SOURCE: HealthSonix, Inc.

October 06, 2006 07:00 ET

TRI-STATE Capital (TSC) Initiates Research Coverage on HealthSonix, Inc. With a Buy Recommendation

IRVINE, CA -- (MARKET WIRE) -- October 6, 2006 -- HealthSonix, Inc. (PINKSHEETS: HSXI) (Frankfurt: H7S) is pleased to announced that TRI-STATE Capital (TSC), has initiated research on the company with a speculative buy recommendation. The research was initiated after the Company announced the expansion of its AquaSonix Therapy programs to the highly respected Baycrest Center in Toronto and to the City owned pools in Guelph. The 12 month target price is $3.50.

TRI-STATE Capital is an independent research organization that specializes in providing research and analysis of publicly held small cap companies. Mr. Michael Grobler, CFA, is the Head of Research with 12 years experience in the micro cap field. To view the entire research report, please click on the attached URL: http://www.otclive.com

"We are happy to have a quality independent research firm like TRI-STATE review our business model and progress to date and to provide the resulting buy recommendation for our stock. This offers further confirmation to our shareholders that our company is headed in the right direction," said Dieter Doederlein, VP Corporate Development. "Our medical technology and treatment programs represent a medical breakthrough in the care of patients suffering from the pain of osteoarthritis," added Dr. David Venturi, Medical Director of HealthSonix. "We recently reached a new milestone by successfully administering over 110,000 treatments without side effects."

About HealthSonix, Inc.

HealthSonix, Inc. (PINKSHEETS: HSXI) (Frankfurt: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.

Forward-Looking Statements:

This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially.

Contact Information